For LEPR rs4655555, a significant association with decreased ER+/PR+ breast cancer risk in the co-dominant genetic model (TT vs. AA, adjusted OR = 0.533, 95% CI = 0.321–0.884, p = 0.015) and the recessive model (TT vs. TA + AA, adjusted OR = 0.562, 95% CI = 0.341–0.925, P = 0.023) was identified. Here, LEPR is linked to breast cancer.